Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1/IDH2 Mutation”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Early research (Phase 1)Study completedNCT02481154
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Who this might be right for
Glioma
Institut de Recherches Internationales Servier 95
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839
What this trial is testing

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Who this might be right for
Acute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more
Shen yang 148
Not applicableStudy completedNCT02986620
What this trial is testing

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
AML, Adult
Gruppo Italiano Malattie EMatologiche dell'Adulto 388
Not applicableLooking for participantsNCT07608003
What this trial is testing

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

Who this might be right for
Gliomas Harboring IDH1 and/or IDH2 MutationsGlioma Glioblastoma MultiformeGlioma of Brainstem+3 more
Xiangya Hospital of Central South University 500
Early research (Phase 1)Not Yet RecruitingNCT07629089
What this trial is testing

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

Who this might be right for
Brain Cancer
Megan Mantica 24
Early research (Phase 1)WithdrawnNCT04955938
What this trial is testing

Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Who this might be right for
IDH MutationIDH1 MutationIDH2 Gene Mutation+2 more
University of Chicago
Not applicableUnknownNCT03204838
What this trial is testing

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Who this might be right for
Acute Myeloid Leukemia (AML)
Hospital General de Mexico 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Not applicableLooking for participantsNCT07315542
What this trial is testing

Diagnostic and Therapeutic Targets in Cartilaginous Tumours

Who this might be right for
ChondrosarcomasCartilage Tumours
St. Anne's University Hospital Brno, Czech Republic 300
Testing effectiveness (Phase 2)Looking for participantsNCT05588141
What this trial is testing

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Who this might be right for
Brain TumorCancer
National Cancer Institute (NCI) 96
Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Looking for participantsNCT07286292
What this trial is testing

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

Who this might be right for
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Institut de Recherches Internationales Servier (I.R.I.S.) 10
Not applicableUnknownNCT03499912
What this trial is testing

Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy

Who this might be right for
Acute Myeloid Leukemia
National Taiwan University Hospital 300
Early research (Phase 1)Study completedNCT02492737
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic SyndromeHematologic Malignancies
Agios Pharmaceuticals, Inc. 46
Testing effectiveness (Phase 2)Study completedNCT03914742
What this trial is testing

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Who this might be right for
IDH1 MutationIDH2 MutationRecurrent Glioblastoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67
Early research (Phase 1)Looking for participantsNCT05873686
What this trial is testing

Clinical Study of NXP900 in Subjects With Advanced Cancers

Who this might be right for
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal Cancer+3 more
Nuvectis Pharma, Inc. 140
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Early research (Phase 1)Looking for participantsNCT07025018
What this trial is testing

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Who this might be right for
Gliomas Harboring IDH1 and/or IDH2 Mutations
Hutchmed 52
Early research (Phase 1)Study completedNCT02071862
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Who this might be right for
Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more
Calithera Biosciences, Inc 210
Next Page